Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГБУЗ «Областная психиатрическая больница им. К.Р. Евграфова»
Список исп. литературыСкрыть список 1. WHO Collaborating Centre for Drug Statistics Methodology [Electronic resource]. URL: http://www.whocc.no. (access date: 02.04.2020). 2. King C, Voruganti LN. What's in a name? The evolution of the nomenclature of antipsychotic drugs. Journal of Psychiatry & Neuroscience. 2002; May. 27(3): 168–75. 3. Мосолов С.Н. Современная антипсихотическая фармакотерапия шизофрении. Неврология. Психиатрия. 2004; 10. / Mosolov S.N. Sovremennaya antipsixoticheskaya farmakoterapiya shizofrenii. Nevrologiya. Psixiatriya. 2004; 10. [in Russian]. 4. A Roadmap to Key Pharmacologic Principles in Using Antipsychotics. The Primary Care Companion to the Journal of Clinical Psychiatry. 2007; 9 (6): 444–54. 5. Гиляровский В.А. Психиатрия. 2 изд. Москва-Ленинград, БИОМЕДГИЗ, 1935 / Gilyarovskij V.A. Psixiatriya. 2 izd. Moskva-Leningrad, BIOMEDGIZ, 1935. [in Russian]. 6. Jones K. Insulin coma therapy in schizophrenia. J Roy Soc Med. 2000; Mar. 93 (3): 147–149. 7. Cerletti, U. Electroshock therapy. In AM Sackler et al. (eds). The Great Physiodynamic Therapies in Psychiatry: an historical appraisal. New York: Hoeber-Harper, 1956. 91–120. 8. Levinson H. The strange and curious history of lobotomy. BBC News. [Electronic resource]. 8 November 2011. URL: http://www.bbc.com/news/magazine-15629160 (access date: 02.04.2020). 9. López-Muñoz F, Alamo C, Cuenca E, et al. History of the discovery and clinical introduction of chlorpromazine. Annals of Clinical Psychiatry. 2005; Jul-Sep. 17 (3): 113–35. 10. Healy D. Explorations in a new world. The creation of psychopharmacology. Harvard University Press. 2004; 77. 11. Granger B, Albu S. The haloperidol story. Ann Clin Psychiatry. 2005; 17(3): 137–140. 12. Riederer P, Laux G, Pöldinger W. Neuro-Psychopharmaka: Ein Therapie-Handbuch Band 1: Allgemeine Grundlagen der Pharmakopsychiatrie. Springer-Verlag Wien GmbH: 1992; 63. 13. Walter S. Drug discovery: a history. New York: Wiley. 2005; 410. 14. Andrew W. Pharmaceutical Manufacturing Encyclopedia. Elsevier. 2013; 1102. 15. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry (12th ed.). London, U K: Wiley-Blackwell. 2015. 16. Riedel M, Müller N, Strassnig M et al. Quetiapine in the treatment of schizophrenia and related disorders. Neuropsychiatric Disease and Treatment. 2007; Apr. 3(2): 219–235. 17. Bachmann C, Lempp T, Glaeske G et al. Antipsychotic prescriptions in children and adolescents—an analysis of data from a German statutory health insurance company from 2005–2012. Dtsch Arztebl Int 2014; 111(3): 25–34. 18. U.S. Food and Drug Administration Center for Drug Evaluation and Research. Novel Drug Approvals for 2015. URL: http://www.fda.gov/drugs/ new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2015 (access date: 02.04.2020). 19. Product information for AusPAR Latuda Commercial Eyes Pty Ltd. Product information Latuda (lurasidone hydrochloride) (PDF). 20 June 2014; URL: http://www.tga.gov.au/sites/default/files/auspar-lurasidone-hydrochloride-140620-pi.pdf (access date: 02.04.2020). 20. Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry. 2005. 7(6): 268–74. 21. Kapur S, Zipursky R, Jones C, et al. Relationship Between Dopamine D(2) Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia. Am J Psychiatry. 2000; Apr. 157(4): 514–20. 22. Kapur S, Zipursky R, Remington G. Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia. Am J Psychiatry. 1999; Feb. 156(2): 286–93. 23. Государственный реестр лекарственных средств [Электронный ресурс]. URL: http://grls.rosminzdrav.ru. (Дата обращения: 02.04.2020). / Gosudarstvennyj reestr lekarstvennyh sredstv [Elektronnyj resurs]. URL: http://grls.rosminzdrav.ru. (Data obrashcheniya: 02.04.2020). [in Russian]. 24. Дробижев М.Ю. Кардиологические аспекты проблемы переносимости и безопасности нейролептика. Психиатрия и психофармакотерапия. 2004; 6(2). / Drobizhev M.Yu. Kardiologicheskie aspekty` problemy` perenosimosti i bezopasnosti nejroleptika. Psixiatriya i psixofarmakoterapiya. 2004; 6(2). [in Russian]. 25. Жаркова Н.Б. Переход к терапии атипичными антипсихотическими средствами — вопрос стратегии или тактики психофармакотерапии? Психиатрия и психофармакотерапия. 2001; 3(1). / Zharkova N.B. Perexod k terapii atipichny`mi antipsixoticheskimi sredstvami — vopros strategii ili taktiki psixofarmakoterapii? Psixiatriya i psixofarmakoterapiya. 2001; 3(1). [in Russian]. 26. Дробижев М.Ю., Овчинников А.А. Зачем нужна современная классификация антипсихотиков? Русский медицинский журнал. 2012; 20(29): 1449–1457. / Drobizhev M.YU., Ovchinnikov A.A. Zachem nuzhna sovremennaya klassifikaciya antipsihotikov? Russkij medicinskij zhurnal. 2012; 20(29): 1449–1457. [in Russian]. 27. Марценковский И.А., Марценковская И.И. Эпилепсия и коморбидные расстройства психики и поведения. Український медичний часопис. 2015; 4: 43–53. / Marcenkovskij I.A., Marcenkovskaya I.I. E`pilepsiya i komorbidny`e rasstrojstva psixiki i povedeniya. Ukraїns`kij medichnij chasopis. 2015; 4: 43–53. [in Russian]. 28. Masaomi I, Shigenori T, Nobuhisa K et al. Optimal Extent of Dopamine D2 Receptor Occupancy by Antipsychotics for Treatment of Dopamine Supersensitivity Psychosis and Late-Onset Psychosis. J Clin Psychopharmacol. 2013; Jun. 33(3): 398–404. 29. Регистр лекарственных средств России [Электронный ресурс]. URL: http://www.rlsnet.ru (Дата обращения: 02.04.2020). / Registr lekarstvennyh sredstv Rossii [Elektronnyj resurs]. URL: http://www.rlsnet.ru (Data obrashcheniya: 02.04.2020). [in Russian]. 30. Рациональный выбор лекарств на основе индекса информационного спроса [Электронный ресурс]. Газета РЛС. 2008. №3. URL: http://www.rlsnet.ru/news_295.htm. (Дата обращения: 02.04.2020). / Racional'nyj vybor lekarstv na osnove indeksa informacionnogo sprosa [Elektronnyj resurs]. Gazeta RLS. 2008. №3. URL: http://www.rlsnet.ru/ news_295.htm. (Data obrashcheniya: 02.04.2020). [in Russian]. 31. Вышковский Г.Л. Методология оптимального выбора фаз маркетингового воздействия при медиапланировании. Реклама. Теория и практика. 2007; 02(20). / Vyshkovskij G.L. Metodologiya optimal'nogo vybora faz marketingovogo vozdejstviya pri mediaplanirovanii. Reklama. Teoriya i praktika. 2007; 02(20). [in Russian]. 32. Free U.S. Outpatient Drug Usage Statistics [Electronic resource]. ClinCalc DrugStats Database. URL: http://clincalc.com/DrugStats/ (access date: 02.04.2020). 33. Справочное руководство по психофармакологическим и противоэпилептическим препаратам, разрешенным к применению в России. Под ред. С.Н. Мосолова. — Изд. 2-е, перераб. — М.: Издательство БИНОМ, 2004; 10–11, 43. / Spravochnoe rukovodstvo po psixofarmakologicheskim i protivoe`pilepticheskim preparatam, razreshenny`m k primeneniyu v Rossii. Pod red. S. N. Mosolova. — Izd. 2-e, pererab. — M.: Izdatel`stvo BINOM, 2004; 10–11, 43. [in Russian]. 34. Ashton H. Drug newsletter. Northern Regional Health Authority. Newcastle upon Tyne: Wolfson Unit of Clinical Pharmacology Royal Victoria Infirmary [Electronic resource]. 1985; Apr 31. URL: http://benzo.org.uk/drcha.htm (access date: 02.04.2020). 35. Benzodiazepine Equivalency Table [Electronic resource]. 2007; Revised April. URL: http://benzo.org.uk/bzequiv.htm. (access date: 02.04.2020). 36. Jakubovski E, Varigonda AL, Freemantle N et al. Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. The American Journal of Psychiatry. 2016; Feb 1; 173 (2): 174–83. 37. Hayasaka Y, Purgato M, Magni LR, et al. Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. J Affect Disord. 2015; 180: 179-184. doi:10.1016/j.jad.2015.03.021 38. Ali IM. Long-term treatment with antidepressants in primary care: Are sub-therapeutic doses still being used? Psychiatric Bulletin. 1998; Jan; 22 (1): 15-19. 39. Atkins M, Burgess A, Bottomley C et al. Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications. Psychiatric Bulletin. 1997; Apr. 21(4): 224–226. 40. Leucht S, Samara M, Heres S et al. Dose Equivalents for Antipsychotic Drugs: The DDD Method. Schizophrenia Bulletin. 2016; 42 Suppl 1(Suppl 1): S90–4. 41. Andreasen N, Pressler M, Nopoulos P et al. Antipsychotic Dose Equivalents and Dose-Years: A Standardized Method for Comparing Exposure to Different Drugs. Biol Psychiatry. 2010; 67(3): 255–262. 42. Woods S. Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics. J Clin Psychiatry. 2003; 64(6): 663–7. 43. Rijcken C, Monster T, Brouwers J et al. Chlorpromazine Equivalents Versus Defined Daily Doses: How to Compare Antipsychotic Drug Doses? J Clin Psychopharmacol. 2003; 23(6): 657–9. 44. Danivas V, Venkatasubramanian G. Current perspectives on chlorpromazine equivalents: Comparing apples and oranges! Indian J Psychiatry. 2013; 55(2): 207–208. 45. Leucht S, Samara M, Heres S et al. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophrenia Bulletin. 2014; 40 (2): 314–326. 46. Leucht S, Samara M, Heres S et al. Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull. 2015; 41(6): 1397–402. 47. Patel M, Arista I, Taylor M et al. How to compare doses of different antipsychotics: a systematic review of methods. Schizophr Res. 2013; 149(1–3): 141–8. 48. Schatzberg A, Cole J, DeBattista C. Manual of Clinical Psychopharmacology. American Psychiatric Publishing. 7th Edition. 2010. 49. Федеральное руководство по использованию лекарственных средств (формулярная система). Под ред. А.Г. Чучалина, Ю.Б. Белоусова, С.П. Голицина и др. Выпуск XIV. М.: Человек и лекарство, 2013. / Federal'noe rukovodstvo po ispol'zovaniiu lekarstvennykh sredstv formuliarnaia sistema). Pod red. A.G.Chuchalina, Iu.B.Belousova, S.P.Golitsina i dr. Vypusk XIV. M.: Chelovek i lekarstvo, 2013. [in Russian]. 50. Leucht S, Crippa A, Siafis S et al. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. American Journal of Psychiatry. 2020; 177(4): 342–353. 51. Пролонгированные нейролептики: между прошлым и будущим. В центре внимания. НЦПЗ РАМН. [Электронный ресурс]. URL: http://www.psychiatry.ru/stat/112. (Дата обращения: 02.04.2020). / Prolongirovanny`e nejroleptiki: mezhdu proshly`m i budushhim. V centre vnimaniya. NCzPZ RAMN. [Elektronnyj resurs]. URL: http://www.psychiatry.ru/stat/112. (Data obrashheniya: 02.04.2020). [in Russian]. 52. WHO Model List of Essential Medicines 18th list (April 2013) (Final Amendments — October 2013) [Electronic resource]. URL: http://www.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf. (access date: 02.04.2020). 53. Gardner D, Murphy A, O’Donnell H. et al. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010; 167(6): 686–93. 54. Sweileh W, Odeh J, Shraim N et al. Evaluation of Defined Daily Dose, percentage of British National Formulary maximum and chlorpromazine equivalents in antipsychotic drug utilization. Saudi Pharmaceutical Journal. 2014; 22(2): 127–32. 55. Филилеева О.В., Мосолов С.Н. Эквивалентные дозировки антипсихотических препаратов. Современная терапия психических расстройств. 2019; 3: 36–44. / Filileeva O.V., Mosolov S.N. E`kvivalentny`e dozirovki antipsixoticheskix preparatov. Sovremennaya terapiya psixicheskix rasstrojstv. 2019; 3: 36–44. [in Russian].